Results 171 to 180 of about 36,038 (221)
A Randomized, Double-Blinded, Placebo-Controlled QTc Study to Evaluate BIA 28-6156 Effect on Cardiac Repolarization in Healthy Volunteers. [PDF]
Clin Pharmacol Drug DevPeixoto I +5 more
europepmc +1 more source
Concurrent moxifloxacin-induced liver injury and toxic epidermal necrolysis after immune checkpoint inhibition: a case report and literature review. [PDF]
Front ImmunolLi Q +6 more
europepmc +1 more source
Treatment Approaches for Refractory <i>Mycoplasma genitalium</i> Infection. [PDF]
Open Forum Infect DisTenney R +3 more
europepmc +1 more source
Abdominal wall abscess due to Mycolicibacterium neworleansense: a case report. [PDF]
BMC Infect DisXiang Y, Fan B, Liu B.
europepmc +1 more source
In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA). [PDF]
J Antimicrob ChemotherLasry D +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1999
Moxilloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing gram-negative and gram-positive bacteria. It has improved activity against gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with ciprofloxacin.
J A, Balfour, L R, Wiseman
openaire +3 more sources
Moxilloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing gram-negative and gram-positive bacteria. It has improved activity against gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with ciprofloxacin.
J A, Balfour, L R, Wiseman
openaire +3 more sources
The Lancet Infectious Diseases, 2012
We believe Helen Cox and colleagues’ proposal to restrict moxifl oxacin use to multidrug-resistant tuberculosis is based on fl awed logic. In a clinical trial of the present fi rst-line regimen for drug-susceptible tuberculosis, cure rates were greater than 95% and no new regimen is likely to improve on this rate.
Kasha Priya, Singh +3 more
openaire +4 more sources
We believe Helen Cox and colleagues’ proposal to restrict moxifl oxacin use to multidrug-resistant tuberculosis is based on fl awed logic. In a clinical trial of the present fi rst-line regimen for drug-susceptible tuberculosis, cure rates were greater than 95% and no new regimen is likely to improve on this rate.
Kasha Priya, Singh +3 more
openaire +4 more sources